REVELIO THERAPEUTICS
Live / Applied — First extension granted (statement of use) (as of 12 Mar 2026)
What this means for you
Not registered yet, but its 18 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98606663
- Mark type
- Stylized text
- Filed
- 18 Jun 2024
- Published for opposition
- 29 Jul 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Therapeutic antibodies for the treatment of cancer; antibody therapeutic preparations for medical purposes for the treatment of cancer; biopharmaceutical preparations for the treatment of cancer
- Class 042 — Scientific and technological services: Scientific research and development services in the field of therapeutic antibodies; research and development of technology in the fields of therapeutic antibodies and biopharmaceuticals
Owner
- Revelio Therapeutics, Inc., New York, NY, US
- Revelio Therapeutics, Inc., New York, NY, US
Prosecution history
- 13 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Mar 2026 — SOU EXTENSION 1 GRANTED
- 12 Mar 2026 — SOU EXTENSION 1 FILED
- 12 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Jul 2025 — PUBLISHED FOR OPPOSITION
- 23 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Jun 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Jun 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 30 Apr 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 30 Apr 2025 — NON-FINAL ACTION E-MAILED
- 30 Apr 2025 — NON-FINAL ACTION WRITTEN